Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
about
TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimenPathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratoriesMetabolic profiles are principally different between cancers of the liver, pancreas and breast.Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment.Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.Germline genetics of cancer of unknown primary (CUP) and its specific subtypesIntegration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists.Changing histopathological diagnostics by genome-based tumor classificationDesmoplastic melanoma with sarcomatoid dedifferentiation.A naive Bayes algorithm for tissue origin diagnosis (TOD-Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system.Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015).Next-generation sequencing: a change of paradigm in molecular diagnostic validation.Cancer of unknown primary: does the key lie in molecular diagnostics?
P2860
Q29122940-4BB26325-8F64-4E6D-9533-C31DACF16ECEQ33602117-B38BD06A-A831-4BCA-B676-6F15843B59E5Q34157807-5C5FFFD1-BCAA-4D27-995A-2C02D17DFF7BQ35068021-50CF45E9-C780-4DFC-9FBB-6D3583182392Q35154126-DD8BD174-2E00-4A53-A7F3-F63C0784B7CAQ35475492-E428E2E2-EE14-4CF2-8BF3-E43E71E254A3Q37225491-85A75882-8110-4538-AC09-F4D54B2BB868Q37416678-66AB6989-94A9-433C-93A3-2193687E3971Q37536877-19B58FEA-20ED-4CAA-B19D-EFE8BD7707ADQ38385463-86406649-AA7A-488C-8374-872F8D904203Q38694763-ABBBE8EA-9CE4-4985-8ABF-C82C85362204Q38828314-139258C2-EAA6-4A91-82AB-BF98FE1AF3D4Q41914832-23152F4B-1CD5-41B9-92DD-BC9E9F83B959Q43232607-E18ECCD8-FA13-4BFE-BE69-FB5068CA115FQ45067635-13D6B496-9D13-4C8E-A52F-18CD16E09EEFQ47768051-E08C3AC5-D4D4-43B9-937D-CFE1AF4688B5Q48162778-34271A21-100C-4F62-9C7C-BD66471D4456Q48606196-EE22543A-0A5B-40BF-9F12-776CF5B3D7B1Q50439480-1B1A22AD-FA51-48E3-97BB-8677CAD306A9
P2860
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Massively-parallel sequencing ...... of cancers of unknown primary.
@en
Massively-parallel sequencing ...... of cancers of unknown primary.
@nl
type
label
Massively-parallel sequencing ...... of cancers of unknown primary.
@en
Massively-parallel sequencing ...... of cancers of unknown primary.
@nl
prefLabel
Massively-parallel sequencing ...... of cancers of unknown primary.
@en
Massively-parallel sequencing ...... of cancers of unknown primary.
@nl
P2093
P2860
P50
P356
P1476
Massively-parallel sequencing ...... of cancers of unknown primary.
@en
P2093
Adam Kowalczyk
Andrew Fellowes
Keith Byron
Linda Mileshkin
Penelope Schofield
Prue Cowin
Terence Siganakis
Timothy Semple
P2860
P304
P356
10.1002/PATH.4251
P577
2013-12-01T00:00:00Z